Cardiac MRI evaluation of myocardial disease

Heart

Volumn 102, Issue 18, 2016, Pages 1429-1435

  Captur, Gabriella ^a,b   Manisty, Charlotte ^a,c   Moon, James C ^a,b,c  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^c ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GADOLINIUM; CONTRAST MEDIUM;

CARBON NUCLEAR MAGNETIC RESONANCE; CARDIAC IMAGING; CARDIOVASCULAR MAGNETIC RESONANCE; CONTRAST ENHANCEMENT; DIAGNOSTIC VALUE; DIFFUSION TENSOR IMAGING; DISEASE CLASSIFICATION; EXTRACELLULAR SPACE; HEART MUSCLE FIBER MEMBRANE STEADY POTENTIAL; HEART MUSCLE FIBROSIS; HEART MUSCLE METABOLISM; HEART PERFORMANCE; HUMAN; INTERDISCIPLINARY RESEARCH; MEASUREMENT ACCURACY; MEASUREMENT PRECISION; MECHANICS; MYOCARDIAL DISEASE; MYOCARDIAL MAPPING; MYOCARDITIS; NONHUMAN; PATIENT CARE; PHENOTYPE; PHOSPHORUS NUCLEAR MAGNETIC RESONANCE; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; REPRODUCIBILITY; REVIEW; SCAR FORMATION; SPECTROSCOPY; STRUCTURE ANALYSIS; TISSUE CHARACTERIZATION; BIOPSY; CARDIAC MUSCLE; CARDIOMYOPATHY; DIAGNOSTIC IMAGING; FIBROSIS; HEART VENTRICLE FUNCTION; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; PATHOPHYSIOLOGY; PREDICTIVE VALUE; PROGNOSIS;

BIOPSY; CARDIOMYOPATHIES; CONTRAST MEDIA; FIBROSIS; HUMANS; MAGNETIC RESONANCE IMAGING; MYOCARDIUM; PREDICTIVE VALUE OF TESTS; PROGNOSIS; REPRODUCIBILITY OF RESULTS; VENTRICULAR FUNCTION;

EID: 84978982759     PISSN: 13556037     EISSN: 1468201X     Source Type: Journal    
DOI: 10.1136/heartjnl-2015-309077     Document Type: Review

References (33)

1. Arbustini E, Narula N, Tavazzi L, et al. The MOGE(S) classification of cardiomyopathy for clinicians. J Am Coll Cardiol 2014;64:304-18.
2. Aye TT, Scholten A, Taouatas N, et al. Proteome-wide protein concentrations in the human heart. Mol Biosyst 2010;6:1917-27.
3. Mohun T, Adams DJ, Baldock R, et al. Deciphering the Mechanisms of Developmental Disorders (DMDD): A new programme for phenotyping embryonic lethal mice. Dis Model Mech 2013;6:562-6.
4. Kramer CM, Barkhausen J, Flamm SD, et al. Standardized cardiovascular magnetic resonance imaging (CMR) protocols, society for cardiovascular magnetic resonance: board of trustees task force on standardized protocols. J Cardiovasc Magn Reson 2008;10:35.
5. Maceira AM, Prasad SK, Khan M, et al. Normalized left ventricular systolic and diastolic function by steady state free precession cardiovascular magnetic resonance. J Cardiovasc Magn Reson 2006;8:417-26.
6. Corona-Villalobos CP, Sorensen LL, Pozios I, et al. Left ventricular wall thickness in patients with hypertrophic cardiomyopathy: A comparison between cardiac magnetic resonance imaging and echocardiography. Int J Cardiovasc Imaging 2016;32:945-54.
7. Flett AS, Maestrini V, Milliken D, et al. Diagnosis of apical hypertrophic cardiomyopathy: T-wave inversion and relative but not absolute apical left ventricular hypertrophy. Int J Cardiol 2015;183:143-8.
8. Suwa K, Satoh H, Sano M, et al. Functional, morphological and electrocardiographical abnormalities in patients with apical hypertrophic cardiomyopathy and apical aneurysm: correlation with cardiac MR. Open Hear 2014;1:e000124.
9. Captur G, Lopes LR, Mohun TJ, et al. Prediction of sarcomere mutations in subclinical hypertrophic cardiomyopathy. Circ Cardiovasc Imaging 2014;7:863-7.
10. Simonetti OP, Kim RJ, Fieno DS, et al. An improved MR imaging technique for the visualization of myocardial infarction. Radiology 2001;218:215-23.
11. Kim RJ, Wu E, Rafael A, et al. The use of contrast-enhanced magnetic resonance imaging to identify reversible myocardial dysfunction. N Engl J Med 2000;343:1445-53.
12. Carlsson M, Wilson M, Martin AJ, et al. Myocardial microinfarction after coronary microembolization in swine: MR imaging characterization. Radiology 2009;250:703-13.
13. Desch S, Eitel I, de Waha S, et al. Cardiac magnetic resonance imaging parameters as surrogate endpoints in clinical trials of acute myocardial infarction. Trials 2011;12:204.
14. Malcolme-Lawes LC, Juli C, Karim R, et al. Automated analysis of atrial late gadolinium enhancement imaging that correlates with endocardial voltage and clinical outcomes: A 2-center study. Heart Rhythm 2013;10:1184-91.
15. Reeder SB, Gulani V. Gadolinium deposition in the brain: do we know enough to change practice? Radiology 2016;279:323-6.
16. Fontana M, Pica S, Reant P, et al. Prognostic value of late gadolinium enhancement cardiovascular magnetic resonance in cardiac amyloidosis. Circulation 2015;132:1570-9.
17. Rashid S, Rapacchi S, Vaseghi M, et al. Improved late gadolinium enhancement MR imaging for patients with implanted cardiac devices. Radiology 2014;270: 269-74.
18. Sado DM, Maestrini V, Piechnik SK, et al. Noncontrast myocardial T1 mapping using cardiovascular magnetic resonance for iron overload. J Magn Reson Imaging 2015;41:1505-11.
19. Sado DM, White SK, Piechnik SK, et al. Identification and assessment of Anderson-Fabry disease by cardiovascular magnetic resonance noncontrast myocardial T1 mapping. Circ Cardiovasc Imaging 2013;6:392-8.
20. Richards DB, Cookson LM, Berges AC, et al. Therapeutic clearance of amyloid by antibodies to serum amyloid P component. N Engl J Med 2015;373: 1106-14.
21. Bohnen S, Radunski UK, Lund GK, et al. Performance of t1 and t2 mapping cardiovascular magnetic resonance to detect active myocarditis in patients with recent-onset heart failure. Circ Cardiovasc Imaging 2015;8:pii: E003073.
22. Ntusi NAB, Piechnik SK, Francis JM, et al. Diffuse myocardial fibrosis and inflammation in rheumatoid arthritis: insights from CMR T1 mapping. JACC Cardiovasc Imaging 2015;8:526-36.
23. Wong TC, Piehler K, Meier CG, et al. Association between extracellular matrix expansion quantified by cardiovascular magnetic resonance and short-Term mortality. Circulation 2012;126:1206-16.
24. Kammerlander AA, Marzluf BA, Zotter-Tufaro C, et al. T1 mapping by CMR imaging: from histological validation to clinical implication. JACC Cardiovasc Imaging 2016;9:14-23.
25. Fontana M, Banypersad SM, Treibel TA, et al. Differential myocyte responses in patients with cardiac transthyretin amyloidosis and light-chain amyloidosis: A cardiac MR imaging study. Radiology 2015;277:388-97.
26. Moon JC, Messroghli DR, Kellman P, et al. Myocardial T1 mapping and extracellular volume quantification: A Society for Cardiovascular Magnetic Resonance (SCMR) and CMR Working Group of the European Society of Cardiology consensus statement. J Cardiovasc Magn Reson 2013;15:92.
27. Holloway CJ, Suttie J, Dass S, et al. Clinical cardiac magnetic resonance spectroscopy. Prog Cardiovasc Dis 2011;54:320-7.
28. Mekkaoui C, Reese TG, Jackowski MP, et al. Diffusion MRI in the heart. NMR Biomed. 2015;20. doi:10.1002/nbm.3426.
29. LaForest R, Woodard PK, Gropler RJ. Cardiovascular PET/MRI: challenges and opportunities. Cardiol Clin 2016;34:25-35.
30. Schuster A, Stahnke VC, Unterberg-Buchwald C, et al. Cardiovascular magnetic resonance feature-Tracking assessment of myocardial mechanics: intervendor agreement and considerations regarding reproducibility. Clin Radiol 2015;70:989-98.
31. Medrano-Gracia P, Cowan BR, Ambale-Venkatesh B, et al. Left ventricular shape variation in asymptomatic populations: The Multi-Ethnic Study of Atherosclerosis. J Cardiovasc Magn Reson 2014;16:56.
32. de Marvao A, Dawes TJW, Shi W, et al. Population-based studies of myocardial hypertrophy: high resolution cardiovascular magnetic resonance atlases improve statistical power. J Cardiovasc Magn Reson 2014;16:16.
33. Goldfarb JW. Abstract 13092: cardiac MRI practice: An analysis of 2012 and 2013 Medicare provider utilization and payment data. Circulation 2015;132: A13092.